Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial

Leone, Antonio Maria; Rutella, Sergio; Giannico, Maria Benedetta; Perfetti, Matteo; Zaccone, Vincenzo; Brugaletta, Salvatore; Garramone, Barbara; Niccoli, Giampaolo; Porto, Italo; Liuzzo, Giovanna; Biasucci, Luigi M.; Bellesi, Silvia; Galiuto, Leonarda; Leone, Giuseppe; Rebuzzi, Antonio Giuseppe; Crea, Filippo

doi:10.1016/j.ijcard.2008.05.036

Cited by 61 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statins increased EPC levels with a peak at 3 to 4 weeks of treatment , whereas a treatment Ͼ4 weeks augmented the late EPC population, which displays higher proliferative potential than early EPC subset (Deschaseaux et al, 2007). Intensive statin treatments (80 versus 20 mg of atorvastatin) have been associated with higher EPC numbers (Leone et al, 2008), whereas longer standard therapeutic regimens (Ͼ8 weeks) have been associated with a reduction in EPC count in the peripheral blood (Hristov et al, 2007), probably because of the increased incorporation of the mobilized EPC into injury sites. The effects of statins on EPC could be due to their pleiotropic activity, because, at least in animal models, no significant changes of serum cholesterol levels were reported.…”

Section: Statins and Endothelial Progenitor Cell Biologymentioning

confidence: 99%

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Gazzerro

Proto²,

Gangemi³

et al. 2011

Pharmacol Rev

401

370

View full text Add to dashboard Cite

Section: Statins and Endothelial Progenitor Cell Biologymentioning

confidence: 99%

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Gazzerro

Proto²,

Gangemi³

et al. 2011

Pharmacol Rev

401

370

View full text Add to dashboard Cite

“…33 Moderate-dose atorvastatin increased CD34 ϩ cells in patients with myocardial infarction 34 and intensive (compared with low-dose) atorvastatin significantly increased CD34 ϩ /KDR ϩ frequency in patients undergoing angioplasty. 35 Although atorvastatin therapy has also been associated with increased circulating progenitor cells in patients with stable coronary artery disease, 36,37 the longer-term effects of statin therapy on progenitor cell quantity have yet to be established. 38 In contrast to the effect of statins, we observed in the present study an inverse correlation between tobacco use and CD34 ϩ frequency, a finding that is consistent with results of a study of circulating CD34 ϩ cells in young, healthy women.…”

Section: Clinical and Genetic Correlates Of Cd34 ϩ Frequency E53mentioning

confidence: 99%

Circulating CD34+ progenitor cell frequency is associated with clinical and genetic factors

Cohen

Cheng

Larson

et al. 2013

Blood

View full text Add to dashboard Cite

Key Points• CD34 ϩ progenitor cell frequency is reduced in older subjects, and is influenced by environmental factors such as smoking and statin use.• CD34 ϩ progenitor cell frequency is highly heritable and associated with common genetic variants at several loci.Circulating blood CD34 ؉ cells consist of hematopoietic stem/progenitor cells, angiogenic cells, and endothelial cells. In addition to their clinical use in hematopoietic stem cell transplantation, CD34 ؉ cells may also promote therapeutic neovascularization. Therefore, understanding the factors that influence circulating CD34 ؉ cell frequency has wide implications for vascular biology in addition to stem cell transplantation. In the present study, we examined the clinical and genetic characteristics associated with circulating CD34 ؉ cell frequency in a large, community-based sample of 1786 Framingham Heart Study participants. Among subjects without cardiovascular disease (n ‫؍‬ 1595), CD34 ؉ frequency was inversely related to older age, female sex, and smoking. CD34 ؉ frequency was positively related to weight, serum total cholesterol, and statin therapy. Clinical covariates accounted for 6.3% of CD34 ؉ variability. CD34 ؉ frequency was highly heritable (h 2 ‫؍‬ 54%; P < .0001). Genome-wide association analysis of CD34 ؉ frequency identified suggestive associations at several loci, including OR4C12 (chromosome 11; P ‫؍‬ 6.7 ؋ 10 ؊7 ) and ENO1 and RERE (chromosome 1; P ‫؍‬ 8.8 ؋ 10 ؊7 ). CD34 ؉ cell frequency is reduced in older subjects and is influenced by environmental factors including smoking and statin use. CD34 ؉ frequency is highly heritable. The results of the present study have implications for therapies that use CD34 ؉ cell populations and support efforts to better understand the genetic mechanisms that underlie CD34 ؉ frequency. (Blood. 2013;121(8):e50-e56)

show abstract

“…The patients in the intensive-care group were loaded aggressively with statins, receiving a minimum of 120 mg of rosuvastatin during the first 48 h after AMI. In previous trials examining the cardioprotective effects of statin therapy, the regimes have been less aggressive and without intensive statin loading [19,20,21]. Thus, it is possible that the cardioprotective effects of statins in our study could have been more pronounced in the intensive-care group than in the usual-care group, and it seems probable that the timeliness of statin initiation could have a crucial role for early LV recovery.…”

Section: Discussionmentioning

confidence: 88%

Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance

Auscher

Løgstrup

Møller³

et al. 2017

Cardiology

View full text Add to dashboard Cite

Objectives: Abnormal glucose tolerance in patients with acute myocardial infarction (AMI) is associated with greater mortality and adverse cardiovascular effects. As statins possess a range of beneficial pleiotropic effects on the cardiovascular system, we sought to assess the cardioprotective effects of statins on left ventricular function in patients with AMI in relation to glycometabolic state. Methods: In a prospective, randomized trial, 140 patients with AMI were randomized to intensive statin therapy receiving statin loading with 80 mg of rosuvastatin followed by 40 mg daily or standard statin therapy. Patients were assessed with an oral glucose tolerance test and their left ventricular (LV) function was assessed with speckle-tracking echocardiography measuring regional longitudinal systolic strain (RLSS) in the infarct area. Results: Overall RLSS in the infarct area improved by a mean (±SD) of -4.22% (±5.19) in the intensive-care group and -2.48% (±4.01) in the usual-care group after 1 month (p = 0.047). In patients with abnormal glucose tolerance, RLSS improved by -5.01% (±5.28) in the intensive-care group and -2.15% (±4.22) in the usual-care group (p = 0.01). Conclusions: Early high-dose statin treatment improved RLSS in the infarct area in patients with AMI, and a trend of greater improvement was seen in patients with abnormal glucose tolerance.

show abstract

Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial

Cited by 61 publications

References 21 publications

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Circulating CD34+ progenitor cell frequency is associated with clinical and genetic factors

Effects of Intensive Statin Therapy on Left Ventricular Function in Patients with Myocardial Infarction and Abnormal Glucose Tolerance

Contact Info

Product

Resources

About